How has been the historical performance of the Hemo Organic?

Answer:The historical performance of Hemo Organic shows a significant increase in net sales, rising from 0.00 Cr in Mar'23 to 2.41 Cr in Mar'25. This growth is notable compared to previous years, where sales were minimal, such as 0.01 Cr in Mar'22 and 0.01 Cr in Mar'21. However, the company has faced challenges with total expenditure, which increased to 2.46 Cr in Mar'25 from 0.27 Cr in Mar'24. Despite the rise in sales, the operating profit (PBDIT) remained negative at -0.05 Cr in Mar'25, although it improved from -0.25 Cr in Mar'24. The profit before tax turned positive at 0.03 Cr in Mar'25, a recovery from -0.26 Cr in Mar'24, leading to a profit after tax of 0.16 Cr in Mar'25, compared to a loss of -0.26 Cr in Mar'24. The earnings per share also improved significantly, reaching 0.46 in Mar'25 from -0.75 in Mar'24. The company's net profit margin showed a positive trend at 6.64% in Mar'25, contrasting sharply with the negative margins in prior years.

Breakdown:
Hemo Organic's financial trajectory has seen a remarkable turnaround in recent years, particularly in net sales, which surged to 2.41 Cr in Mar'25 from negligible amounts in earlier years. While total operating income also increased to 2.41 Cr, the total expenditure rose sharply to 2.46 Cr, indicating rising costs that outpaced revenue growth. The operating profit, although still negative, showed signs of improvement, and the company achieved a profit before tax of 0.03 Cr in Mar'25, marking a significant recovery from previous losses. This led to a profit after tax of 0.16 Cr, a stark contrast to the losses recorded in the prior year. The earnings per share reflected this positive shift, moving from a loss of -0.75 to a profit of 0.46, while the net profit margin turned positive at 6.64%, highlighting a potential for future profitability amidst prior financial struggles.